Cheetah Medical, a Tel-Aviv, Israel-based developer of a noninvasive hemodynamic and cardiac output monitoring technology, closed a $20m financing round.
The financing was led by Ascension Health Ventures (AHV), with participation from Robert Bosch Venture Capital (RBVC), MVM Life Science Partners (MVM) and existing investors.
In conjunction with the financing, Dr. Walter Lin, an Investment Manager with AHV, Gadi Toren, Venture Capital Investment Partner with RBVC, and Dr. Stephen Reeders, a Managing Partner with MVM, have joined the company’s board.
Cheetah Medical’s NICOM(R) Noninvasive Cardiac Output and Hemodynamic Monitoring System uses the company’s proprietary BIOREACTANCE(R) Technology to deliver continuous and accurate cardiac output and other vital hemodynamic monitoring parameters.
It can be utilized by physicians, nurses and other clinicians.
The system is US FDA cleared and CE Marked, and since its commercial launch in 2008 has been adopted by a growing number of clinicians worldwide.
The company’s US headquarters is located in Portland, Oregon.